Copyright
©The Author(s) 2021.
World J Gastroenterol. Dec 28, 2021; 27(48): 8343-8356
Published online Dec 28, 2021. doi: 10.3748/wjg.v27.i48.8343
Published online Dec 28, 2021. doi: 10.3748/wjg.v27.i48.8343
Figure 2 Estimating two- and five-year hepatocellular carcinoma disease-free survival by using Kaplan-Meier method according to the squamous cell carcinoma antigen immunocomplex, alpha-fetoprotein and combination of those in estimation cohort.
A: Squamous cell carcinoma antigen immunocomplex (SCCA-IgM); low-risk: < 124 AU/mL, high-risk: > 124 AU/mL; B: Alpha-fetoprotein (AFP); low-risk: < 5 ng/mL, high-risk: > 5 ng/mL; C: Combination of SCCA-IgM and AFP. AFP: Alpha-fetoprotein; SCCA-IgM: Squamous cell carcinoma antigen immunocomplex.
- Citation: Gil-Gómez A, Rojas Á, Liu CH, Gallego-Duran R, Muñoz-Hernandez R, Fassina G, Pontisso P, Ampuero J, Romero-Gómez M. Combination of squamous cell carcinoma antigen immunocomplex and alpha-fetoprotein in mid- and long-term prediction of hepatocellular carcinoma among cirrhotic patients. World J Gastroenterol 2021; 27(48): 8343-8356
- URL: https://www.wjgnet.com/1007-9327/full/v27/i48/8343.htm
- DOI: https://dx.doi.org/10.3748/wjg.v27.i48.8343